Initial results from the phase-1 clinical trial revealed the favorable activity of Cevostamab in heavily pre-treated relapsed/refractory MM [106] and whether 1q amp/gain MM may respond better to FcRH5 targeted by Cevostamab needs to be investigated further. The gene discussed is FCRL5; the disease is Miyoshi myopathy.